Want to see IN:ANUHPHR full AI Analyst Report?
Top Page
Anuh Pharma Limited
(ANUHPHR)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹97.00
▲(25.11% Upside)
Action:Reiterated
Date:09/08/26
The score is primarily driven by mixed fundamentals: strong revenue growth and a very conservative balance sheet are offset by meaningful margin compression and a sharp deterioration to negative operating/free cash flow. Technically, the stock is in an uptrend but appears overextended (high RSI), while valuation looks broadly fair with only modest yield support.
Positive Factors
Revenue Growth
Strong multi-period revenue expansion indicates that Anuh Pharma is increasing sales of its API and bulk-drug products. Continued top-line growth can improve operating scale, support investment in manufacturing capabilities, and strengthen the company’s ability to absorb fixed compliance and production costs.
Negative Factors
Margin Compression
The sharp decline in gross and net margins shows that higher sales are currently converting into less profit. If weaker product mix or cost pressure persists, operating leverage will be reduced, earnings growth may lag revenue growth, and the company’s ability to reinvest from internally generated profits could weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong multi-period revenue expansion indicates that Anuh Pharma is increasing sales of its API and bulk-drug products. Continued top-line growth can improve operating scale, support investment in manufacturing capabilities, and strengthen the company’s ability to absorb fixed compliance and production costs.
Read all positive factors
Anuh Pharma Limited (ANUHPHR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹9.11B
Dividend Yield1.66%
Average Volume (3M)23.75K
Price to Earnings (P/E)20.5
Beta (1Y)0.69
Revenue Growth9.70%
EPS Growth21.04%
CountryIN
Employees323
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.00
Shares Outstanding100,224,000
10 Day Avg. Volume21,751
30 Day Avg. Volume23,746
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)1.91
Price to Sales (P/S)0.87
P/FCF Ratio-61.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Anuh Pharma Limited Business Overview & Revenue Model
Company Description
Anuh Pharma Ltd. is an Indian enterprise specializing in the manufacturing and distribution of bulk drugs and various chemical compounds. The company provides a comprehensive selection of active pharmaceutical ingredients (APIs), encompassing macr...
How the Company Makes Money
Anuh Pharma Limited primarily makes money by selling active pharmaceutical ingredients (APIs) and related bulk drug products to customers such as pharmaceutical formulation companies and other drug manufacturers. Revenue is recognized from the sal...
Anuh Pharma Limited Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
88
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.84B | 7.72B | 6.62B | 6.47B | 5.27B | 4.87B |
| Gross Profit | 910.30M | 1.34B | 1.62B | 1.60B | 1.26B | 1.09B |
| EBITDA | 329.27M | 660.76M | 703.64M | 872.47M | 573.89M | 520.43M |
| Net Income | 200.69M | 410.46M | 473.52M | 600.58M | 361.80M | 305.61M |
Balance Sheet | ||||||
| Total Assets | 5.09B | 5.57B | 5.07B | 4.46B | 4.05B | 3.47B |
| Cash, Cash Equivalents and Short-Term Investments | 135.33M | 531.61M | 734.15M | 622.56M | 530.77M | 252.65M |
| Total Debt | 2.27M | 583.00K | 108.86M | 26.93M | 9.07M | 42.23M |
| Total Liabilities | 1.82B | 2.05B | 1.81B | 1.54B | 1.64B | 1.33B |
| Stockholders Equity | 3.27B | 3.52B | 3.26B | 2.91B | 2.41B | 2.14B |
Cash Flow | ||||||
| Free Cash Flow | -58.52M | -108.42M | 169.79M | 79.08M | 523.51M | 272.49M |
| Operating Cash Flow | 121.88M | -29.73M | 371.25M | 129.25M | 539.02M | 288.64M |
| Investing Cash Flow | 162.28M | 172.97M | -199.09M | 9.18M | -434.84M | -78.17M |
| Financing Cash Flow | -294.46M | -258.22M | -48.60M | -85.68M | -122.87M | -194.49M |
Anuh Pharma Limited Technical Analysis
Positive
77.53
Price Trends
82.51
Positive
79.91
Positive
78.07
Positive
Market Momentum
3.16
Positive
55.43
Neutral
40.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANUHPHR, the sentiment is Positive. The current price of 77.53 is below the 20-day moving average (MA) of 89.22, below the 50-day MA of 82.51, and below the 200-day MA of 78.07, indicating a bullish trend. The MACD of 3.16 indicates Positive momentum. The RSI at 55.43 is Neutral, neither overbought nor oversold. The STOCH value of 40.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ANUHPHR.
Anuh Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹9.11B | 20.50 | ― | 1.66% | 9.70% | 21.04% | |
63 Neutral | ₹7.60B | 25.41 | ― | 0.40% | 14.04% | 2.57% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹4.97B | 22.10 | ― | 0.57% | 11.43% | 258.53% | |
50 Neutral | ₹7.55B | 168.88 | ― | 0.15% | 7.55% | -57.19% | |
49 Neutral | ₹7.88B | 12.96 | ― | 1.20% | 3.63% | 24.22% | |
46 Neutral | ₹11.60B | 44.24 | ― | 0.34% | -9.58% | ― |
* General Sector Average
IN:ANUHPHR
Anuh Pharma Limited
90.30
8.82
10.82%
IN:ALBERTDAVD
Albert David Ltd
871.60
97.57
12.61%
IN:KILITCH
Kilitch Drugs (India) Limited
223.55
54.10
31.93%
IN:SIGACHI
Sigachi Industries Limited
29.42
-8.55
-22.51%
IN:WANBURY
Wanbury Limited
224.00
-23.30
-9.42%
IN:ZIMLAB
Zim Laboratories Ltd.
138.45
65.09
88.73%
Anuh Pharma Limited Corporate Events
Anuh Pharma Clears Board Reappointments, Auditor Mandate and Governance Overhaul
Aug 14, 2026
Anuh Pharma Limited has approved several management and governance changes at its 66th Annual General Meeting, including the reappointment of non-executive non-independent directors Bipin Nemchand Shah and Arun Lalchand Todarwal. The meeting also ...
Anuh Pharma Shareholders Clear Board Reappointments and Governance Updates
Aug 14, 2026
Anuh Pharma Limited has reported that shareholders at its 66th Annual General Meeting approved the reappointment of two non-executive non-independent directors and the cost auditor for the financial year ending March 2027. The company also approve...
Anuh Pharma Publishes Q1 FY27 Unaudited Results in Newspapers
Aug 9, 2026
Anuh Pharma Limited has published newspaper notices announcing the availability of its unaudited financial results for the quarter ended 30 June 2026. The results were carried in the Financial Express (English) and Mumbai Lakshdeep (Marathi) on 9 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.